A Phosphorylatable Sphingosine Analog Induces Airway Smooth Muscle Cytostasis and Reverses Airway Hyperresponsiveness in Experimental Asthma. - Wikidata - wikimedia - TriplyDB

A Phosphorylatable Sphingosine Analog Induces Airway Smooth Muscle Cytostasis and Reverses Airway Hyperresponsiveness in Experimental Asthma.

A Phosphorylatable Sphingosine Analog Induces Airway Smooth Muscle Cytostasis and Reverses Airway Hyperresponsiveness in Experimental Asthma.

http://www.wikidata.org/entity/Q37653912

about

A Phosphorylatable Sphingosine Analog Induces Airway Smooth Muscle Cytostasis and Reverses Airway Hyperresponsiveness in Experimental Asthma.

http://www.wikidata.org/entity/Q37653912

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 21 February 2017

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

A Phosphorylatable Sphingosine ...... veness in Experimental Asthma.

@en

A Phosphorylatable Sphingosine ...... veness in Experimental Asthma.

@nl

type

label

A Phosphorylatable Sphingosine ...... veness in Experimental Asthma.

@en

A Phosphorylatable Sphingosine ...... veness in Experimental Asthma.

@nl

prefLabel

A Phosphorylatable Sphingosine ...... veness in Experimental Asthma.

@en

A Phosphorylatable Sphingosine ...... veness in Experimental Asthma.

@nl

P1433

Q37653912-3F8D7CE2-4B86-4C7A-AF6A-3BE581ACC9CA

P1476

Q37653912-02EE98B8-8536-43BB-BFDE-B3C428DD5AE4

P2093

Q37653912-267B6235-F534-45A4-A3F1-7B1D6D49A66B

Q37653912-323BA9CB-F608-46A8-B1F5-19D7BD5FA789

Q37653912-404EC786-AF0B-4A3A-A886-DABD7AF3B619

Q37653912-416F4432-EB83-4971-8383-C90FA451FB44

Q37653912-4BE0468E-9FC5-4F79-848A-23B9F8889BF6

Q37653912-6D6F80E3-8988-456D-8E3C-FCDBBA7876C0

Q37653912-80884611-2265-4D0A-8FDC-6E9765047574

Q37653912-95568D38-0962-40BF-9E00-3FC3C52F4DAC

Q37653912-ACDC4F24-5F3B-453D-93B9-D0783CE66619

Q37653912-B82D6F04-057D-439E-A9B0-B270D0F7E931

P2860

Q37653912-05846EAC-B1D7-47A9-9491-D27058E23C80

Q37653912-069B135C-6718-4CE6-82EC-02CBB8E065D5

Q37653912-06D87AC1-7AE6-4BFF-BB40-82FB1329DC35

Q37653912-14BC621B-B50B-4729-8921-6CD6494C6596

Q37653912-15D1A4C8-03C8-4769-8078-BE8A2583E37D

Q37653912-171AD6A6-25CD-42AF-8330-1813F19FFE46

Q37653912-18030509-E6FF-4EF4-B4AC-97D609075F85

Q37653912-1B31A3C3-3AE7-4BB4-B7C7-7C636147B86A

Q37653912-2391E933-CC07-4647-A603-C14007BC44EC

Q37653912-277C0674-F2A7-4E20-9DDB-37EDEADA2A7A

P304

Q37653912-49A13E15-C53F-41B9-A284-62F83E574AC9

P31

Q37653912-B3F0494F-1BAD-42B0-ACA4-0EBC8D443067

P356

Q37653912-51F084AB-97B6-4AAC-9974-A2F7E90A68C6

P478

Q37653912-E3880AEA-9F5A-4ED5-87F2-1385D2C4A3ED

P50

Q37653912-65DEEED1-A520-4DEF-9F8F-401F22724450

Q37653912-85CF06B3-FEA1-44EC-B071-1F20CE9DE1BA

P577

Q37653912-39A79471-1D45-4B04-9EFD-8F85CE11EBE6

P698

Q37653912-59EDC1A3-E1B5-4395-9C30-EF55318D17FF

P921

Q37653912-7AFD0B8B-884F-4ACE-9DCB-978EF12F49DC

P932

Q37653912-1C48F557-CF08-48E7-B099-B50F937EB5B3

P356

FPHAR.2017.00078

P1433

Frontiers in Pharmacology

P1476

A Phosphorylatable Sphingosine ...... veness in Experimental Asthma.

@en

P2093

Anne-Marie Lemay

http://www.w3.org/2001/XMLSchema#string

Audrey Lee-Gosselin

http://www.w3.org/2001/XMLSchema#string

Carole-Ann Huppé

http://www.w3.org/2001/XMLSchema#string

David Marsolais

http://www.w3.org/2001/XMLSchema#string

David R Gendron

http://www.w3.org/2001/XMLSchema#string

Marie-Josée Beaulieu

http://www.w3.org/2001/XMLSchema#string

Marie-Renée Blanchet

http://www.w3.org/2001/XMLSchema#string

Mathieu Laplante

http://www.w3.org/2001/XMLSchema#string

Nicolas Flamand

http://www.w3.org/2001/XMLSchema#string

Pascale B Lecours

http://www.w3.org/2001/XMLSchema#string

P2860

A summary of the new GINA strategy: a roadmap to asthma control

Differential effects of rapamycin and dexamethasone in mouse models of established allergic asthma

Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis

Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists

Bronchial thermoplasty: Long-term safety and effectiveness in patients with severe persistent asthma

Antigen-specific CD4+ T cells drive airway smooth muscle remodeling in experimental asthma.

The sphingosine 1-phosphate transporter, SPNS2, functions as a transporter of the phosphorylated form of the immunomodulating agent FTY720.

FTY720 and (S)-FTY720 vinylphosphonate inhibit sphingosine kinase 1 and promote its proteasomal degradation in human pulmonary artery smooth muscle, breast cancer and androgen-independent prostate cancer cells

Prolonged exposure to sphingosine 1-phosphate receptor-1 agonists exacerbates vascular leak, fibrosis, and mortality after lung injury.

Modulation of chemokines and allergic airway inflammation by selective local sphingosine-1-phosphate receptor 1 agonism in lungs

P304

78

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3389/FPHAR.2017.00078

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P50

Sylvain Bourgoin

P577

2017-02-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28270767

http://www.w3.org/2001/XMLSchema#string

P921

P932

5318459

http://www.w3.org/2001/XMLSchema#string